A study to evaluate the therapeutic equivalence of a new multidose budesonide dry powder inhaler with a conventional budesonide dry powder inhaler Source: Eur Respir J 2001; 18: Suppl. 33, 156s Year: 2001
Pharmaceutical performances of formoterol delivered from a novel multidose dry powder inhaler Source: Eur Respir J 2001; 18: Suppl. 33, 134s Year: 2001
Long-term preference and ease of use of a novel dry powder inhaler with budesonide in comparison to a conventional inhaler in asthmatic children Source: Eur Respir J 2001; 18: Suppl. 33, 121s Year: 2001
Beclometasone/formoterol administered via extrafine dry powder inhaler in controlled asthmatic patients: Comparison with pMDI and beclometasone monotherapy Source: Annual Congress 2012 - Trials in asthma: asthma exacerbations and severe asthma Year: 2012
Oral manifestations in asthmatic patients using metered dose inhaler and dry powder inhaler Source: International Congress 2019 – Innovations in primary care assessment and management Year: 2019
Clinical equivalence of budesonide delivered via two dry powder inhalers Source: Eur Respir J 2005; 26: Suppl. 49, 339s Year: 2005
Reliability of inhalation therapy through a multidose dry powder inhaler Source: Annual Congress 2007 - Respiratory issues in primary care Year: 2007
The genuair® inhaler: a novel multidose dry powder inhaler for the delivery of various types of inhalation powder Source: Annual Congress 2009 - New aspects of inhalation therapy Year: 2009
Once-daily budesonide: clinical equivalence of two dry powder inhalers (DPIs) Source: Eur Respir J 2005; 26: Suppl. 49, 339s Year: 2005
Formoterol: a new pMDI CFC free formulation. Efficacy of the 12µg dosage versus a dry powder inhaler in moderate to severe asthmatic patients Source: Eur Respir J 2003; 22: Suppl. 45, 284s Year: 2003
Formoterol delivered by multi-dose dry powder inhaler (MDDPI) improves nocturnal asthma symptoms Source: Eur Respir J 2005; 26: Suppl. 49, 50s Year: 2005
Comparison of two dry powder inhalers containing budesonide in the treatment of asthma in children Source: Eur Respir J 2002; 20: Suppl. 38, 500s Year: 2002
Effect of switching from salmeterol/fluticasone dry powder inhaler to formoterol/fluticasone pressurized metered-dose inhaler in elderly asthma patients Source: International Congress 2016 – Asthma management Year: 2016
Salbutamol delivered via a new multi-dose dry powder inhaler is as safe and efficacious as a pressurised metered dose inhaler in children aged 6-12 years Source: Eur Respir J 2002; 20: Suppl. 38, 501s Year: 2002
Young children with asthma treated with budesonide inhalation suspension can successfully be transitioned to once-daily budesonide dry powder inhaler Source: Annual Congress 2007 - Anti-inflammatory therapy for childhood asthma Year: 2007
Urinary cortisol levels following 400 mcg budesonide twice daily from a novel multi-dose dry powder inhaler compared to a conventional dry powder inhaler in children Source: Eur Respir J 2001; 18: Suppl. 33, 289s Year: 2001
Comparison of the release characteristics of formoterol dihydrate powder for inhalation delivered through two different types of multidose dry powder inhalers (MDPI) Source: Eur Respir J 2005; 26: Suppl. 49, 126s Year: 2005
Comparison of a formoterol multiple dose dry powder inhaler (MDPI) with a formoterol single dose dry powder inhaler (SDPI) in patients with moderate to severe asthma Source: Eur Respir J 2004; 24: Suppl. 48, 260s Year: 2004
Flow-dependent performance of several formoterol dry powder inhalers (DPIs) Source: Eur Respir J 2006; 28: Suppl. 50, 435s Year: 2006
Bronchodilator effect of formoterol delivered by two different dry powder inhalers (DPI) Source: Eur Respir J 2004; 24: Suppl. 48, 310s Year: 2004